



25

26 Carlos Conde ([cconde@ibmc.up.pt](mailto:cconde@ibmc.up.pt)) ORCID: 0000-0002-4177-8519.

27 Rua Alfredo Allen 208,

28 4200-135, Porto, Portugal

29 +351 22 607 4900

30

31 João Claro ([jclaro@fe.up.pt](mailto:jclaro@fe.up.pt)) ORCID: 0000-0001-5936-1036

32 INESC TEC and Faculdade de Engenharia, Universidade do Porto, Campus da FEUP, Rua

33 Dr. Roberto Frias, 4200-465 Porto, Portugal

34 +351 22 508 1400

35

36 **Key Words for use by abstracting services:** epilepsy, medical devices, user involvement,

37 medical device design

38

39 Number of text pages: 43

40 Number of words: 4507

41 Number of references: 90

42 Number of figures: 6

43 Number of tables: 3

44

45

46

47

48

49

## 50 **ABSTRACT**

51 **Objective** This systematic review aims to describe the involvement of persons with epilepsy  
52 (PWE), healthcare professionals (HP) and caregivers (CG) in the design and development of  
53 medical devices is epilepsy.

54 **Methods:** A systematic review was conducted, adhering to the Preferred Reporting Items for  
55 Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Eligibility criteria included  
56 peer-reviewed research focusing on medical devices for epilepsy management, involving  
57 users (PWE, CG, and HP) during the MDD process. Searches were performed on PubMed,  
58 Web of Science, and Scopus, and a total of 55 relevant articles were identified and reviewed.

59 **Results:** From 1999 to 2023, there was a gradual increase in the number of publications  
60 related to user involvement in epilepsy medical device development (MDD), highlighting the  
61 growing interest in this field. The medical devices involved in these studies encompassed a  
62 range of seizure detection tools, healthcare information systems, vagus nerve stimulation  
63 (VNS) and electroencephalogram (EEG) technologies reflecting the emphasis on seizure  
64 detection, prediction, and prevention. PWE and CG were the primary users involved,  
65 underscoring the importance of their perspectives. Surveys, usability testing, interviews, and  
66 focus groups were the methods employed for capturing user perspectives. User involvement  
67 occurs in four out of the five stages of MDD, with production being the exception.

68 **Significance** User involvement in the MDD process for epilepsy management is an emerging  
69 area of interest holding a significant promise for improving device quality and patient  
70 outcomes. This review highlights the need for broader and more effective user involvement,  
71 as it currently lags in the development of commercially available medical devices for  
72 epilepsy management. Future research should explore the benefits and barriers of user  
73 involvement to enhance medical device technologies for epilepsy.

74

## 75 **Plain Language Summary**

76 This review covers studies that have involved users in the development process of medical  
77 devices for epilepsy. The studies reported here have focused on getting input from people  
78 with epilepsy, their caregivers, and healthcare providers. These devices include tools for  
79 detecting seizures, stimulating nerves, and tracking brain activity. Most user feedback was  
80 gathered through surveys, usability tests, interviews, and focus groups. Users were involved  
81 in nearly every stage of device development except production. The review highlights that  
82 involving users can improve device quality and patient outcomes, but more effective  
83 involvement is needed in commercial device development. Future research should focus on  
84 the benefits and challenges of user involvement.

85

86 **Keywords:** epilepsy, medical devices, user involvement, medical device design

## 87 **Key Point Box**

- 88 - PWE are the users more involved in the MDD process;
- 89 - Surveys and usability testing are the methods more frequently used for user  
90 involvement in the MDD process in epilepsy;
- 91 - Literature only discloses the involvement of users in the MDD process of 13  
92 commercially available medical devices for epilepsy management.

## 93 **1. INTRODUCTION**

94 Epilepsy impacts approximately 70 million individuals and 30 % of them do not respond to  
95 current treatments to control their seizures <sup>1</sup>. Accurately anticipating the onset of seizures and  
96 managing them can assist PWE in avoiding self-injury and potentially enhance their overall  
97 well-being. Seizure detection and, more recently, seizure forecasting are critical areas of  
98 clinical advancement in epilepsy. The progress in these areas has been driven by

99 developments in medical devices, which have the potential to optimize seizure control and  
100 prevent seizure-related morbidity and mortality in individuals with epilepsy <sup>2</sup>.

101 Medical devices used in epilepsy range from implantable devices such as vagus nerve  
102 stimulators, responsive neurostimulation and deep brain stimulation to non-implantable  
103 devices such as electroencephalography (EEG) based systems and non-EEG based seizure  
104 detection wearable devices <sup>1</sup>. Regardless of the type of medical device, the ultimate goal is to  
105 develop devices that meet the needs of end-users (PWE, CGs and HP), improve disease  
106 outcomes, and enhance the overall quality of life of individuals with epilepsy.

107 Medical device manufacturers create life-changing innovations through the collaborative  
108 expertise of various disciplines, including engineering, manufacturing, clinical, regulatory,  
109 marketing, sales, and business specialists. While cutting-edge technology advancement in  
110 medical device design is absolutely vital, it is the overall experience (cognitive and  
111 emotional) that impacts the daily life of the patient and CG <sup>3</sup>. In recent years, there has been a  
112 growing recognition of the importance of user involvement in MDD in general <sup>4</sup>, and  
113 specifically for epilepsy <sup>5</sup>. In epilepsy, user involvement refers to the active participation of  
114 PWE, CGs, HP and other stakeholders in the design and development of medical devices.  
115 Understanding and incorporating users' needs, preferences, and feedback into the MDD  
116 process can help to ensure that the device is effective, safe, and well-received by the intended  
117 users. User involvement can take various forms, including needs assessment, usability  
118 testing, co-creation and co-design <sup>6</sup>. User-centred design is a critical factor in the design and  
119 development of medical devices. Specifically, considering user needs during the early stages  
120 of device conceptualization and throughout the subsequent development process can yield  
121 substantial benefits. This approach can improve patient safety, increase compliance with  
122 treatment regimens, and enhance health outcomes <sup>7</sup>. Additionally, user-centred design  
123 promotes higher levels of user satisfaction, and it can lead to a reduction in device

124 development time by identifying and addressing usability issues prior to launch. This, in turn,  
125 can help to avoid costly design changes and product recalls, which can have significant  
126 financial and reputational implications for device manufacturers <sup>8</sup>. Therefore, successful  
127 medical device innovation requires investigation of end-user and broader stakeholder  
128 contexts and incorporation of those context-specific needs into design processes <sup>9</sup>.

129 Despite the initial promise that user involvement in medical device design and development  
130 for epilepsy holds, there is widespread scepticism regarding its effectiveness within the  
131 scientific, medical, and general communities, leaving important choices and questions open  
132 for debate, namely: (i) who should be involved, (ii) at which stages should they be involved,  
133 (iii) which participatory methods are most suitable and (iv) what topics are to be discussed  
134 with end users during development. Therefore, we conducted a systematic review to explore  
135 the practice of user involvement in the design and development of medical devices for  
136 epilepsy, aiming to provide valuable insights into the role of user involvement in this context  
137 and inform future research and practice in this area. Descriptive statistics and qualitative  
138 thematic analysis were used for analysing the data, which were divided into different themes,  
139 i.e., types of medical devices developed and assessed; types of medical device users involved;  
140 extent of user involvement by different stages of the MDD cycle; and methods used for  
141 capturing users' perspectives.

## 142 **2. METHODS**

143 The present systematic literature review was performed to identify and extract all currently  
144 available literature related to user involvement in medical devices or technology utilized in  
145 the monitoring, treatment and/or management of epilepsy.

## 146 **2.1 Protocol and registration**

147 This systematic review was reported according to the Preferred Reporting Items for  
148 Systematic Reviews and Meta-Analyses (PRISMA) guidelines <sup>10</sup>, and was prospectively  
149 registered on the International Prospective Register of Systematic Reviews (PROSPERO)  
150 (CRD42023490599).

## 151 **2.2 Eligibility Criteria**

152 Publications inclusion and eligibility for short-listing criteria encompassed (a) peer-reviewed  
153 original research, (b) targeted only at medical devices according to WHO's definition <sup>11</sup> with  
154 application for epilepsy management and (c) indicating user (PWE, CG and HP) involvement  
155 during these products' development lifecycle.

156 Original publications were excluded if presenting any of the following characteristics: the  
157 wrong population (i.e., non-human population); the wrong intervention (i.e., medical devices  
158 used for other purposes rather than epilepsy management); the wrong outcome (i.e., there  
159 were no epilepsy or seizure diagnosis, management, or treatment outcomes); publication not  
160 available in the English language; publications not in full publication. All studies published  
161 up to 30 November 2023 were included with no other time limitations.

## 162 **2.3 Search strategy**

163 Search strings related to medical devices, users' (PWE, CG and HP) involvement and  
164 epilepsy were developed. Thus, the search term ("epilepsy") was searched in combination  
165 with the following search strings: ("device users" OR "end-users" OR "medical devices" OR  
166 "medical device users" OR "needs assessment" OR "new medical technology" OR "user  
167 centered product" OR "user criteria" OR "user input" OR "user interests" OR "user  
168 involvement" OR "user needs" OR "user needs assessment" OR "user needs research" OR  
169 "user participation" OR "user perceptions" OR "user perspective" OR "user requirements"

170 OR “user requirements elicitation” OR “user studies” or “user survey” OR “user-based” OR  
171 “wearable device” OR “device” and “acceptability” OR (“device” AND “usability”) OR  
172 (“device” AND “satisfaction”) OR (“device” AND “patient views”). The Boolean operator  
173 AND was used to link the search term with the respective search strings on all databases.

174 Three databases were used from database inception on 30 November 2023: PubMed, Web of  
175 Science and Scopus. All searches were performed based on the title, abstract and keyword in  
176 all databases. Articles were first screened through their titles and abstracts before proceeding  
177 with the full-text screening of relevant articles. The search criteria and keywords were arrived  
178 at through consensus with all researchers. Hand searching, personal collections (unpublished  
179 studies, conference abstracts, grey literature, or other resources that researchers have  
180 accumulated through personal networks or professional contacts) and exploding references  
181 (reviewing the reference lists of relevant articles to identify additional studies that may not  
182 have been captured through our primary search strategy) were also used to augment the  
183 results.

#### 184 **2.4 Selection Process**

185 Database search results were imported into EndNote (EndNote x9; Clarivate, Philadelphia,  
186 PA, USA), and duplicates were removed. Results were then exported to an Excel spreadsheet  
187 for title, abstract, and full-text screening. Study selection, data extraction and assessment of  
188 study quality followed the Standards for Reporting Qualitative Research<sup>13</sup>. No assumptions  
189 were made during the selection to reduce the risk of bias. Each paper was screened and  
190 discussed by two independent reviewers (JF, RP). Disagreements were resolved by a third  
191 independent researcher (CC).



## 192 **2.5 Data collection and analysis**

193 Data was extracted using a data-extraction form (Appendix 1.) developed for the review <sup>14</sup>.  
194 Data extracted included: (1) author details, (2) year of publication, (3) country of study, (4)  
195 type of medical device, (5) method/tool/approach, (6) users and (7) product development  
196 stages. Since there is no standard framework to describe the MDD stages <sup>15</sup>, for data  
197 extraction purposes, the medical device lifecycle was divided into five stages: 1- Concept; 2-  
198 Design; 3-Testing and Trials; 4- Production; 5-Deployment. The classification of medical  
199 device lifecycle stages was carried out based on the product lifecycle reported in the literature  
200 (Table 1 adapted from Shah, Robinson <sup>16</sup>).

201

## 202 **3. RESULTS**

203 The study workflow and paper selection process is illustrated in Figure 1. Following the  
204 inclusion criteria review, 55 publications (<sup>17 18 19 20 21 22 23 24 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35,</sup>  
205 <sup>36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66,</sup>  
206 <sup>67, 68, 69, 70, 71</sup>) were included, and 109 were excluded (see Figure 1 for PRISMA flow chart).

207 Seventeen of the 55 included publications were from the United States, 7 from the United  
208 Kingdom, 6 from Canada, 5 from Denmark, 4 from The Netherlands, 3 from Germany and 3  
209 from South Korea and 1 from Sweden, 1 from Mexico, 1 from France, 1 from Italy and 1  
210 from Belgium. Five studies were of multiple origin (Table S1).

211 Across the years, we find that user involvement in MDD is becoming more frequent. Figure 2  
212 shows the number of papers published per year and the total accumulated number of  
213 publications over time since the inaugural paper by Hufford, R.L., P.M. <sup>72</sup>.

214

### 215 **3.1 Types of medical devices assessed by user involvement.**

216 In our comprehensive review, we have identified a broad spectrum of medical devices (as  
217 illustrated in Figure 3) that have been conceived and rigorously assessed by involving end-  
218 users. The majority of the devices were seizure detection devices (44%) and healthcare /  
219 clinical information systems (40%) such as Software as Medical Device, web-based tools,  
220 electronic health records, and videoconferencing systems. Vagus Nerve Stimulator systems  
221 represented 9% of the studies found, followed by EEG (5%) and 1 study on an automated  
222 injection system (2%).

223

### 224 **3.2 Types of medical devices users involved in MDD and assessment.**

225 A wide range of users were involved in the MDD process, including clinicians, PWE, carers,  
226 family members and persons with different disabilities and impairments (Figure 4). PWE  
227 were the users more frequently involved (40%, N = 3), followed by the PWE alongside CG  
228 (27%, N = 15) and HP (11%, N = 6). CG and HP alone were the users less frequently  
229 involved.

230

### 231 **3.3 Extent of user involvement by stage of the medical device lifecycle**

232 The findings of the selected studies, especially the stages of the development of new medical  
233 devices, and methods used for capturing user perspectives by stages of the medical device  
234 lifecycle, are summarized in Figure 5 and Table S1. In 93% (N= 51) of the studies, users  
235 were involved in one stage of the medical device lifecycle especially in the deployment stage,  
236 and in the remaining studies users were involved in 2 (5%, N = 3) or 3 (2%, N = 1) stages of  
237 the lifecycle. Single-stage involvement was predominant in the deployment phase during  
238 which the product is already in the market, as reported in 45% (N = 25) of the studies,

239 followed by concept stages in 25% (N = 14), when all uncertainties such as the clinical need  
240 definition, customer requirements and needs, finances, reimbursement strategy, team  
241 selection, or legal aspects must be considered. Two-stage combinations were between design  
242 and testing and trials in 5% (N = 3). Three-stage combinations for user involvement were  
243 between concept, design, and testing and trials stages in 2% (N = 1), which is shown in  
244 Figure 5.

245 All other studies are less comprehensive as their models only encompass one stage.

246

### 247 **3.4 Methods used for capturing users' perspectives**

248 Our review shows that several methods were designed to involve users, often requiring the  
249 combination of both qualitative methods to evaluate parameters from a numerical point of  
250 view and quantitative methods to indicate the user's choices, thoughts, and feelings.  
251 Involving users and capturing their perspectives in the medical device technology lifecycle  
252 concerned mostly surveys in 49% (N=43), usability testing in 20% (N=18), interviews in  
253 19% (N=17), and focus groups in 11% (N=10) of the studies (Figure 6). These methods are  
254 mapped against the medical device lifecycle stages where they were used (Table 2). Some of  
255 the studies used more than one method of inquiry.

256 Surveys and focus groups were used in all four medical device lifecycle stages where the  
257 users were involved. Typically, surveyed individuals were asked to respond to the questions  
258 in a yes/no manner, on a Likert-type scale (e.g., very often to not at all often), or with open-  
259 ended responses. The choice of responses was dictated by the investigator and the medical  
260 device (if one was used). The selection of the type of response desired was often made based  
261 on the difficulty of the question asked and the depth of knowledge and level of precision the  
262 investigator would like to have about a particular factor <sup>74</sup>.

263 Usability tests and interviews were most commonly used for involving users and capturing  
264 their perspectives across three stages of the medical device lifecycle. During usability tests,  
265 various data collection methods were used to collect both qualitative and quantitative data.  
266 Results such as time to complete tasks, or errors made during tasks, were easy to understand  
267 and compare. In its simplest form, a usability test just involved users performing a number of  
268 typical tasks and then reporting their experiences of using the device, i.e., what, in their  
269 opinion, worked well and what was problematic in the device placement <sup>43</sup>. When testing an  
270 existing or prototype device to identify areas for improvement for example, qualitative data  
271 was more useful <sup>47</sup>. In some of the reviewed studies, the developers observed users  
272 performing scenario-based usability tests to identify shortcomings or areas for improvement  
273 <sup>49</sup> and/or asked the user to report their experiences in follow-up interviews <sup>56</sup> or through user-  
274 centered methods such as empathy interviews, empathy mapping, and persona development  
275 as they complete the task <sup>64</sup>. Sometimes quantitative data were collected during usability  
276 tests, such as the time taken to complete a task using the device or the number of errors made  
277 whilst performing the task <sup>42</sup>. Interviews were mainly semi-structured and face-to-face. The  
278 factors on which information was routinely collected in these studies include socio-  
279 demographic characteristics, lifestyle practices, medical history, and use of medical devices.

280 Finally, our systematic review revealed that almost half of the papers we retrieved  
281 incorporated 2 or more methods to evaluate user perspectives throughout the MDD process.  
282 For example, a scoping method such as exploratory interviews <sup>65</sup> or a focus group <sup>51</sup> were  
283 used to specify the needs and requirements of the users with an evaluative method such as a  
284 usability test <sup>65</sup> or survey <sup>51</sup> then used respectively at a later stage to determine whether these  
285 have been met.

286

## 287 **4. DISCUSSION**

288 Successful medical device innovation requires research beyond technology-centred or technocentric  
289 design approaches to embrace user-centred methods <sup>9</sup>. Employing formal methods to involve users  
290 in the MDD process should increase the probability that devices meet proper clinical goals, comply  
291 with technical standards, are cost-effective and meet ethical norms <sup>75</sup>.

292

### 293 **4.1 Types of devices**

294 In this review a substantial proportion of the devices pertained to seizure detection, and  
295 healthcare and clinical information systems. This distribution aligns with previous studies <sup>77</sup>,  
296 <sup>78</sup> that highlight the predominant focus on seizure forecasting and detection in epilepsy  
297 research, underscoring the profound impact of seizures' unpredictability in this condition.  
298 Notably, only 5 VNS and 3 EEG based systems were found in our literature search.  
299 Moreover, among the 23 commercially available seizure detection devices and tools in the  
300 US and Europe, reported by Shum, Friedman <sup>79</sup>, only Nightwatch, Epicare, Epilog, Sensor  
301 Dots and GeneActiv were identified to have involved users in the MDD process  
302 predominantly in the deployment phase <sup>27, 37, 39, 50</sup>. This indicates a notable discrepancy in the  
303 extent of user involvement in the development of commercially available devices for epilepsy  
304 management. As highlighted by Hagedorn, Krishnamurty, Grosse <sup>80</sup>, the disclosure of user  
305 involvement might be limited due to safety, privacy, and other ethical concerns that are  
306 unique to medical environments and contexts. Nevertheless, these results highlight a potential  
307 area for further research and improvement.

### 308 **4.2 Types of users**

309 The development of better products requires an in-depth understanding of all types of users,  
310 their activities, and their needs <sup>81</sup>. In epilepsy, prior research has demonstrated that

311 distinctions among users, including PWE, CG or HP can influence the delineation of user-  
312 specific requirements <sup>28</sup>. Consequently, similar factors were appropriately considered in this  
313 study. Our review reveals that various types of medical devices are developed and assessed  
314 by PWE, CG and HP. These different groups of healthcare technology users' characteristics,  
315 skills and working environment may be different, which is worth considering when  
316 developing health care technologies from the users' perspective. It must be mentioned,  
317 however, that in assessing user needs, there is a substantial bias towards considering the  
318 needs of HP in contrast to PWE and CG. It is vital, therefore, that a range of users are  
319 consulted to get as wide an array of input as possible <sup>82</sup>. Our review showed that PWE and  
320 CG are the users more involved in the MDD process. These users are likely to be a non-  
321 medical, heterogeneous group, including family members. As a result, their background, age,  
322 level of training, physical and mental fitness, and language knowledge vary considerably.  
323 Furthermore, the context of use is hard to predict and likely to be less controlled, when  
324 compared to a healthcare setting where standardised procedures and protocols are usually in  
325 effect. Therefore, understanding their individual needs is imperative for a successful device  
326 development process, and product quality and safety <sup>14, 16</sup>, which might be the reason why  
327 these are more involved.

### 328 **4.3 Methods of involvement**

329 In the process of designing and developing medical devices, biomedical innovators have at  
330 their disposal a range of formal methods to incorporate user requirements. Our review shows  
331 that four methods were used to involve users in the MDD process, despite several other  
332 available approaches could have been considered such as heuristic evaluation, journey  
333 mapping<sup>83</sup>, and cognitive walkthrough <sup>84</sup>. The majority of the studies used surveys, probably  
334 due to their effectiveness in gathering user feedback, namely through scalability, cost-  
335 effectiveness, standardization of data, anonymity, and quick data collection <sup>85</sup>. With

336 increasing attention being paid to patient-reported outcomes by funding agencies, measures  
337 of patient-centred factors, such as quality of life, depression, anxiety, cognitive, and  
338 functional status, are increasingly included in these surveys. Usability evaluation was the  
339 second most used method, reported in 20% of the reviewed studies, probably due to the  
340 current focus on improving usability and reducing human error within the medical device  
341 industry, and their need for regulatory agencies' certification <sup>86</sup>.

342 Depending on the purpose and context of the medical device, understanding user needs and  
343 eliciting their perspectives for developing medical devices could entail a combination of  
344 different methods <sup>14</sup>. Our systematic review revealed that nearly half of the papers we  
345 retrieved incorporated two or more methods to evaluate user perspectives throughout the  
346 MDD process. The identified use of multiple qualitative and quantitative methods in  
347 combination with specific design methods is in line with the most recent literature which  
348 highlights the importance of multi-method human-centred design approaches for the  
349 development of health innovations comprising several design cycles <sup>87</sup>.

350

#### 351 **4.4 Stages of MDD**

352 Human-centred design should be central to all MDD to ensure that user needs are met. It is  
353 recommended that user-centred design should begin early, and continue throughout device  
354 development <sup>88</sup>. Although we have found that users were involved in four out of the five  
355 stages of the MDD process - concept, design, testing and trials, and deployment stages - none  
356 of the medical devices identified was assessed in all of these four stages. Moreover the  
357 predominance of studies found in the deployment phase suggests that devices may lack  
358 sufficient user input during their development, since the form and function has already been  
359 determined, and the ability to innovate based on user needs is limited due to a number of

360 fixed parameters<sup>3</sup>. Consequently, the medical devices found in this review may only partially  
361 meet user requirements or fail to meet user requirements which could result in suboptimal  
362 user experiences, higher modification costs, and missed opportunities for innovation.

363

#### 364 **4.5 Regulatory view**

365 Despite the fact that regulatory authorities such as Food and Drug Administration (FDA) and  
366 European Medicines Agencies (EMA) and international standards organizations have  
367 increasingly emphasized the importance of the employing formal methods for users'  
368 involvement in the MDD as a critical factor in ensuring the effectiveness, safety, and  
369 usability of medical devices<sup>89, 90</sup>, the involvement of users in the MDD process in epilepsy  
370 remains marginal. Our systematic review revealed that users were only involved in the MDD  
371 process of 13 commercially available medical devices for epilepsy management with most of  
372 the involvement being performed at the end of the MDD process in the deployment phase.  
373 These results are in line with other therapeutic areas, as medical device manufacturers often  
374 do not consider the benefit of employing formal human factors engineering methods within  
375 the MDD process<sup>7</sup>. This gap suggests that the appropriate employment of formal methods by  
376 manufacturers is unlikely to occur to significant levels without deliberate efforts to encourage  
377 and support manufacturers in doing so. Alternatively, the implementation of such methods  
378 could assume a mandatory character, being dictated to manufacturers by standards and  
379 purchasing agencies.

#### 380 **5. LIMITATIONS**

381 This systematic review adopted the MDD cycle comprising 5 phases accordingly with Shah,  
382 Robinson<sup>16</sup>. However, there is a lack of standardization of the MDD life cycle phases. WHO  
383 has yet to publish the medical device innovation part of the WHO medical device technical



384 series, where it is expected to contribute to the standardization of the stages of the MDD  
385 process. Moreover, one limitation of this systematic review lies in the potential exclusion of  
386 medical devices developed by HP, whose contributions, though integral to the development  
387 phase, may not be explicitly reported in dedicated studies. Moreover, our review is contingent  
388 on published studies, and thus, it might not capture unpublished research, proprietary  
389 assessments by companies, or start-up initiatives aimed at gathering end-users' feedback. This  
390 limitation highlights the potential underrepresentation of critical insights and developments in  
391 the field. The underreporting of user involvement in the MDD process, especially in epilepsy  
392 management, results in a missed opportunity for the broader medical community.  
393 Theoretically, once IP rights are secured, companies could safely disclose their methods of  
394 user involvement without jeopardizing their competitive position. However, the prevalent  
395 medical device industry practice of non-disclosure prevents the sharing of potentially  
396 beneficial experiences. Such transparency could foster an environment of collaborative  
397 improvement, motivating others to adopt user-centric approaches in device development. The  
398 lack of published information on user involvement methods in peer-reviewed journals hinders  
399 the opportunity for cross-learning and iterative enhancements in medical device design. This  
400 gap in knowledge dissemination ultimately impacts the quality and efficacy of devices  
401 developed for epilepsy care, as well as other medical fields. Additionally, our review found  
402 only 55 papers on user involvement or acceptability, likely because these metrics are often  
403 embedded within the paper rather than highlighted in the abstract or title. This may have  
404 inadvertently excluded relevant studies, suggesting there could be more instances of user  
405 involvement not captured in our review.

## 406 **6. CLINICAL RELEVANCE OR FUTURE DIRECTIONS**

407 This article provides a review and a conceptual understanding of the main user involvement  
408 research trends in MDD. The reviewed studies examined the medical-device usability

409 concept from three viewpoints: PWE, CGs and HPs. In this review, 55 scientific sources  
410 related to user involvement in the medical device design and development in epilepsy were  
411 analysed and systematized. The following were discussed: (i) PWE are the users more  
412 involved in the MDD process; (ii) actual assessments may be applied differently for different  
413 medical devices with a higher prevalence for surveys and usability testing; (iii) formal  
414 methods for user involvement in the MDD process can be selected differently depending on  
415 the type of product; (iv) users are involved in 4 stages of the MDD process; (v) although  
416 regulatory guidelines are published to address user involvement in MDD process, future  
417 formal guidelines are needed to promote widespread of user involvement in MDD process in  
418 epilepsy.

419

#### 420 **Author Contributions**

421 J.F., R.P., C.C., J.C. and L.L. were responsible for conceptualisation, study design,  
422 and search strategy for this Review. J.F. and R.P. carried out the systematic review. C.C.  
423 adjudicated disagreements. J.F. carried out the statistical analyses. J.F. and R.R. drafted the  
424 manuscript. All authors critically revised the manuscript, approved its submitted version, and  
425 accept responsibility for its content. The article is the original work of the authors and has not  
426 been previously published, nor is it currently under consideration by any other journal.

427

#### 428 **Acknowledgments**

429 This systematic review was funded by the European Union. Views and opinions  
430 expressed are however those of the author(s) only and do not necessarily reflect those of the  
431 European Union or European Innovation Council and SMEs Executive Agency (EISMEA).  
432 Neither the European Union nor the granting authority can be held responsible for them. The

433 work of J.C. is partially financed by National Funds through the Portuguese funding agency,  
434 FCT - Fundação para a Ciência e a Tecnologia, within project LA/P/0063/2020. DOI  
435 10.54499/LA/P/0063/2020 | <https://doi.org/10.54499/LA/P/0063/2020>. C.C. is supported by a  
436 Scientific Employment Stimulus contract (2020.00067.CEECIND) from Fundação para a  
437 Ciência e a Tecnologia.

438

#### 439 **Disclosure of Conflicts of Interest**

440 The authors declare no competing interests.

441

#### 442 **Ethical Approval**

443 We confirm that we have read the Journal's position on issues involved in ethical  
444 publication and affirm that this report is consistent with those guidelines.

445

## 446 **7. REFERENCES**

- 447 1. Ong JS, Wong SN, Arulsamy A, Watterson JL, Shaikh MF. Medical Technology: A  
448 Systematic Review on Medical Devices Utilized for Epilepsy Prediction and Management Curr  
449 Neuropharmacol. 2022;20:950-964.
- 450 2. Hubbard I, Beniczky S, Ryvlin P. The Challenging Path to Developing a Mobile Health  
451 Device for Epilepsy: The Current Landscape and Where We Go From Here Front Neurol.  
452 2021;12:740743.
- 453 3. Dunn JL, Ko KHK, Lahoud D, Nusem E, Straker K, Wrigley C. Exploring the role of design  
454 in the context of medical device innovation. In: Almendra RA, editor. Proceedings of the Academy  
455 for Design Innovation Management Conference 2019. United Kingdom: Academy for Design  
456 Innovation Management; 2019. p. 1-19.

- 457 4. FDA. Applying Human Factors and Usability Engineering to Medical Devices. 2016.
- 458 5. Bruno E, Viana PF, Sperling MR, Richardson MP. Seizure detection at home: Do devices on  
459 the market match the needs of people living with epilepsy and their caregivers? *Epilepsia*. 2020  
460 Nov;61 Suppl 1:S11-S24.
- 461 6. Vaisson G, Provencher T, Dugas M, Trottier ME, Chipenda Dansokho S, Colquhoun H, et al.  
462 User Involvement in the Design and Development of Patient Decision Aids and Other Personal Health  
463 Tools: A Systematic Review *Med Decis Making*. 2021 Apr;41:261-274.
- 464 7. Money AG, Barnett J, Kuljis J, Craven MP, Martin JL, Young T. The role of the user within  
465 the medical device design and development process: medical device manufacturers' perspectives  
466 *BMC Medical Informatics and Decision Making*. 2011 2011/02/28;11:15.
- 467 8. Arthur G Money JB, Jasna Kuljis, Michael P Craven, Jennifer L Martin, Terry Young. The  
468 role of the user within the medical device design and development process: medical device  
469 manufacturers' perspectives *BMC Medical Informatics and Decision Making*. 2011;11:12.
- 470 9. Rodriguez NM, Burleson G, Linnes JC, Sienko KH. Thinking Beyond the Device: An  
471 Overview of Human- and Equity-Centered Approaches for Health Technology Design *Annu Rev*  
472 *Biomed Eng*. 2023 Jun 8;25:257-280.
- 473 10. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The  
474 PRISMA 2020 statement: an updated guideline for reporting systematic reviews *BMJ*. 2021 Mar  
475 29;372:n71.
- 476 11. WHO. Global Model Regulatory Framework for Medical Devices including in vitro  
477 diagnostic medical devices. 2017.
- 478 12. Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and  
479 SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative  
480 systematic reviews *BMC Health Serv Res*. 2014 Nov 21;14:579.
- 481 13. O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative  
482 research: a synthesis of recommendations *Acad Med*. 2014 Sep;89:1245-1251.
- 483 14. Shah SG, Robinson I, AlShawi S. Developing medical device technologies from users'  
484 perspectives: a theoretical framework for involving users in the development process *Int J Technol*  
485 *Assess Health Care*. 2009 Oct;25:514-521.

- 486 15. Maresova P, Klimova B, Honegr J, Kuca K, Ibrahim WNH, Selamat A. Medical Device  
487 Development Process, and Associated Risks and Legislative Aspects-Systematic Review Front Public  
488 Health. 2020;8:308.
- 489 16. Shah SG, Robinson I. User involvement in healthcare technology development and  
490 assessment: structured literature review Int J Health Care Qual Assur Inc Leadersh Health Serv.  
491 2006;19:500-515.
- 492 17. Hufford BJ, Glueckauf RL, Webb PM. Home-based, interactive videoconferencing for  
493 adolescents with epilepsy and their families Rehabilitation Psychology. 1999;44:176-193.
- 494 18. Zamponi N, Rychlicki F, Corpaci L, Cesaroni E, Trignani R. Vagus nerve stimulation (VNS)  
495 is effective in treating catastrophic 1 epilepsy in very young children Neurosurg Rev. 2008  
496 Jul;31:291-297.
- 497 19. DiIorio C, Escoffery C, McCarty F, Yeager KA, Henry TR, Koganti A, et al. Evaluation of  
498 WebEase: an epilepsy self-management Web site Health Educ Res. 2009 Apr;24:185-197.
- 499 20. Schulze-Bonhage A, Sales F, Wagner K, Teotonio R, Carius A, Schelle A, et al. Views of  
500 patients with epilepsy on seizure prediction devices Epilepsy Behav. 2010 Aug;18:388-396.
- 501 21. Koo YS, Yang KS, Seok HY, Lee SK, Lee IK, Cho YW, et al. Characteristics of patients with  
502 epilepsy who use a website providing healthcare information about epilepsy in South Korea Epilepsy  
503 Behav. 2012 Oct;25:156-161.
- 504 22. Vonhofen G, Evangelista T, Lordeon P. Nursing benefits of using an automated injection  
505 system for ictal brain single photon emission computed tomography J Neurosci Nurs. 2012  
506 Apr;44:91-95; quiz 96-97.
- 507 23. Thygesen KS, Sabers A. Promising effect of vagal stimulation in Danish patients with  
508 epilepsy Dan Med J. 2013 Mar;60:A4597.
- 509 24. Brunnhuber F, Amin D, Nguyen Y, Goyal S, Richardson MP. Development, evaluation and  
510 implementation of video-EEG telemetry at home Seizure. 2014 May;23:338-343.
- 511 25. Askamp J, van Putten MJ. Mobile EEG in epilepsy Int J Psychophysiol. 2014 Jan;91:30-35.
- 512 26. Hoppe C, Feldmann M, Blachut B, Surges R, Elger CE, Helmstaedter C. Novel techniques for  
513 automated seizure registration: Patients' wants and needs Epilepsy Behav. 2015 Nov;52:1-7.

- 514 27. van Andel J, Leijten F, van Delden H, van Thiel G. What makes a good home-based  
515 nocturnal seizure detector? A value sensitive design PLoS One. 2015;10:e0121446.
- 516 28. Van de Vel A, Smets K, Wouters K, Ceulemans B. Automated non-EEG based seizure  
517 detection: Do users have a say? *Epilepsy Behav.* 2016 Sep;62:121-128.
- 518 29. Newman C, Shankar R, Hanna J, McLean B, Osland A, Milligan C, et al. Developing an  
519 Evidence-Based Epilepsy Risk Assessment eHealth Solution: From Concept to Market *JMIR Res*  
520 *Protoc.* 2016 Jun 7;5:e82.
- 521 30. Patel AD, Moss R, Rust SW, Patterson J, Strouse R, Gedela S, et al. Patient-centered design  
522 criteria for wearable seizure detection devices *Epilepsy Behav.* 2016 Nov;64:116-121.
- 523 31. Sauro KM, Holroyd-Leduc J, Wiebe S, Quan H, Cooke L, Cross JH, et al. Knowledge  
524 translation of an online tool to determine candidacy for epilepsy surgery evaluation *Neurol Clin Pract.*  
525 2016 Aug;6:304-314.
- 526 32. Tovar Quiroga DF, Britton JW, Wirrell EC. Patient and caregiver view on seizure detection  
527 devices: A survey study *Seizure.* 2016 Oct;41:179-181.
- 528 33. Modi AC, Schmidt M, Smith AW, Turnier L, Glaser N, Wade SL. Development of a web-  
529 based executive functioning intervention for adolescents with epilepsy: The Epilepsy Journey  
530 *Epilepsy Behav.* 2017 Jul;72:114-121.
- 531 34. Ali R, Elsayed M, Kaur M, Air E, Mahmood N, Constantinou J, et al. Use of social media to  
532 assess the effectiveness of vagal nerve stimulation in Dravet syndrome: A caregiver's perspective *J*  
533 *Neurol Sci.* 2017 Apr 15;375:146-149.
- 534 35. Halford JJ, Sperling MR, Nair DR, Dlugos DJ, Tatum WO, Harvey J, et al. Detection of  
535 generalized tonic-clonic seizures using surface electromyographic monitoring *Epilepsia.* 2017  
536 Nov;58:1861-1869.
- 537 36. Ozanne A, Johansson D, Hallgren Graneheim U, Malmgren K, Bergquist F, Alt Murphy M.  
538 Wearables in epilepsy and Parkinson's disease-A focus group study *Acta Neurol Scand.* 2018  
539 Feb;137:188-194.
- 540 37. Arends J, Thijs RD, Gutter T, Ungureanu C, Cluitmans P, Van Dijk J, et al. Multimodal  
541 nocturnal seizure detection in a residential care setting: A long-term prospective trial *Neurology.* 2018  
542 Nov 20;91:e2010-e2019.

- 543 38. Afra P, Bruggers CS, Sweney M, Fagatele L, Alavi F, Greenwald M, et al. Mobile Software  
544 as a Medical Device (SaMD) for the Treatment of Epilepsy: Development of Digital Therapeutics  
545 Comprising Behavioral and Music-Based Interventions for Neurological Disorders *Front Hum*  
546 *Neurosci.* 2018;12:171.
- 547 39. Meritam P, Ryvlin P, Beniczky S. User-based evaluation of applicability and usability of a  
548 wearable accelerometer device for detecting bilateral tonic-clonic seizures: A field study *Epilepsia.*  
549 2018 Jun;59 Suppl 1:48-52.
- 550 40. Janse SA, Dumanis SB, Huwig T, Hyman S, Fureman BE, Bridges JFP. Patient and caregiver  
551 preferences for the potential benefits and risks of a seizure forecasting device: A best-worst scaling  
552 *Epilepsy Behav.* 2019 Jul;96:183-191.
- 553 41. Chiang S, Moss R, Patel AD, Rao VR. Seizure detection devices and health-related quality of  
554 life: A patient- and caregiver-centered evaluation *Epilepsy Behav.* 2020 Apr;105:106963.
- 555 42. Bruno E, Biondi A, Thorpe S, Richardson MP, Consortium R-C. Patients self-mastery of  
556 wearable devices for seizure detection: A direct user-experience *Seizure.* 2020 Oct;81:236-240.
- 557 43. Bruno E, Biondi A, Bottcher S, Lees S, Schulze-Bonhage A, Richardson MP, et al. Day and  
558 night comfort and stability on the body of four wearable devices for seizure detection: A direct user-  
559 experience *Epilepsy Behav.* 2020 Nov;112:107478.
- 560 44. Khan A, Peechatka A, Dias NR, Lima V, Seddo M, Inja A, et al. Patient Perspective in the  
561 Development of Electronic Patient-Reported Outcomes (ePROs) in Seizure Disorders: A Patient-  
562 Centric Approach *Patient Prefer Adherence.* 2020;14:13-21.
- 563 45. Beck M, Simony C, Zibrandtsen I, Kjaer TW. Readiness among people with epilepsy to carry  
564 body-worn monitor devices in everyday life: A qualitative study *Epilepsy Behav.* 2020  
565 Nov;112:107390.
- 566 46. Thompson ME, Goodwin R, Ojeda A, Morris L, Fairman AD. User Preferences for the  
567 Design of a Mobile Health System to Support Transition-Age Youth With Epilepsy *J Pediatr Health*  
568 *Care.* 2020 May-Jun;34:e28-e36.
- 569 47. Simblett S, Matcham F, Curtis H, Greer B, Polhemus A, Novak J, et al. Patients'  
570 Measurement Priorities for Remote Measurement Technologies to Aid Chronic Health Conditions:  
571 Qualitative Analysis *JMIR Mhealth Uhealth.* 2020 Jun 10;8:e15086.

- 572 48. Simblett SK, Biondi A, Bruno E, Ballard D, Stoneman A, Lees S, et al. Patients' experience  
573 of wearing multimodal sensor devices intended to detect epileptic seizures: A qualitative analysis  
574 *Epilepsy Behav.* 2020 Jan;102:106717.
- 575 49. Yoo S, Lim K, Baek H, Jang SK, Hwang GY, Kim H, et al. Developing a mobile epilepsy  
576 management application integrated with an electronic health record for effective seizure management  
577 *Int J Med Inform.* 2020 Feb;134:104051.
- 578 50. Nasser M, Nurse E, Glasstetter M, Bottcher S, Gregg NM, Laks Nandakumar A, et al. Signal  
579 quality and patient experience with wearable devices for epilepsy management *Epilepsia.* 2020  
580 Nov;61 Suppl 1:S25-S35.
- 581 51. Buchhalter JR, Scantlebury MH, D'Alfonso S, Pablo Appendino J, Bello Espinosa L, Brooks  
582 BL, et al. Creation and implementation of an electronic health record note for quality improvement in  
583 pediatric epilepsy: Practical considerations and lessons learned *Epilepsia Open.* 2021 Jun;6:345-358.
- 584 52. Grzeskowiak CL, Dumanis SB. Seizure Forecasting: Patient and Caregiver Perspectives *Front*  
585 *Neurol.* 2021;12:717428.
- 586 53. Cote J, Beaudet L, Auger P, Rouleau G, Chicoine G, Leger V, et al. Evaluation of a web-  
587 based virtual nursing intervention to support self-management among adults with epilepsy: A mixed-  
588 methods study *Epilepsy Behav.* 2021 Jan;114:107581.
- 589 54. Bruno E, Biondi A, Richardson MP, Consortium O. Digital semiology and time-evolution  
590 pattern of bio-signals in focal onset motor seizures *Seizure.* 2021 Apr;87:114-120.
- 591 55. Herrera-Fortin T, Bou Assi E, Gagnon MP, Nguyen DK. Seizure detection devices: A survey  
592 of needs and preferences of patients and caregivers *Epilepsy Behav.* 2021 Jan;114:107607.
- 593 56. Olsen LS, Nielsen JM, Simony C, Kjaer TW, Beck M. Wearables in real life: A qualitative  
594 study of experiences of people with epilepsy who use home seizure monitoring devices *Epilepsy*  
595 *Behav.* 2021 Dec;125:108398.
- 596 57. Willems LM, Baier H, Bien CG, Bosebeck F, Dumpelmann M, Hamer HM, et al. Satisfaction  
597 with and reliability of in-hospital video-EEG monitoring systems in epilepsy diagnosis - A German  
598 multicenter experience *Clin Neurophysiol.* 2021 Sep;132:2317-2322.
- 599 58. Monfort E, Poulet C, Nahas C, Bakridan S, Clair L, Latour P. Clustering patients and  
600 caregivers for technology design: A step prior to the design of an innovative technological device for  
601 the detection of epileptic seizures *Epilepsy Behav.* 2021 Sep;122:108233.



- 602 59. Chiang S, Moss R, Black AP, Jackson M, Moss C, Bidwell J, et al. Evaluation and  
603 recommendations for effective data visualization for seizure forecasting algorithms JAMIA Open.  
604 2021 Jan;4:ooab009.
- 605 60. Sabers A, Aumuller-Wagner S, Christensen LR, Henning O, Kostov K, Lossius M, et al.  
606 Feasibility of transcutaneous auricular vagus nerve stimulation in treatment of drug resistant epilepsy:  
607 A multicenter prospective study *Epilepsy Res.* 2021 Nov;177:106776.
- 608 61. Siegel BI, Johnson M, Dawson TE, Kurzen E, Holt PJ, Wolf DS, et al. Reducing Prescribing  
609 Errors in Hospitalized Children on the Ketogenic Diet *Pediatr Neurol.* 2021 Feb;115:42-47.
- 610 62. von Wrede R, Rings T, Schach S, Helmstaedter C, Lehnertz K. Transcutaneous auricular  
611 vagus nerve stimulation induces stabilizing modifications in large-scale functional brain networks:  
612 towards understanding the effects of taVNS in subjects with epilepsy *Sci Rep.* 2021 Apr 12;11:7906.
- 613 63. Hadady L, Klivenyi P, Fabo D, Beniczky S. Real-world user experience with seizure  
614 detection wearable devices in the home environment *Epilepsia.* 2022 Feb 23.
- 615 64. Schmidt M, Glaser N, Riedy T, Rietta C, Huszti H, Wagner J, et al. Learning experience  
616 design of an mHealth intervention for parents of children with epilepsy *Int J Med Inform.* 2022  
617 Apr;160:104671.
- 618 65. Lazaro MJ, Alvaran A, Yun MH, Kim S. Mobile Health Application for Seizure  
619 Management: A Human-Systems Integration Approach *Hum Factors.* 2022 Mar  
620 25:187208221074427.
- 621 66. Macea J, Bhagubai M, Broux V, De Vos M, Van Paesschen W. In-hospital and home-based  
622 long-term monitoring of focal epilepsy with a wearable electroencephalographic device: Diagnostic  
623 yield and user experience *Epilepsia.* 2023 Apr;64:937-950.
- 624 67. van Leeuwen MMA, Droger MM, Thijs RD, Kuijper B. Nocturnal seizure detection: What  
625 are the needs and expectations of adults with epilepsy receiving secondary care? *Epilepsy Behav.*  
626 2023 Oct;147:109398.
- 627 68. Guerrero-Aranda A, Friman-Guillen H, González-Garrido AA. Acceptability by End-users of  
628 a Standardized Structured Format for Reporting EEG Clinical EEG and neuroscience. 2023  
629 Sep;54:483-488.

- 630 69. Lewis-Fung S, Tchao D, Gray HG, Nguyen E, Pardini S, Harris LR, et al. Designing virtual  
631 reality exposure scenarios to treat anxiety in people with epilepsy: Phase 2 of the AnxEpiVR clinical  
632 trial. 2023 2023-July-19;4. Original Research
- 633 70. Tchao D, Lewis-Fung S, Gray H, Pardini S, Harris LR, Appel L. Describing epilepsy-related  
634 anxiety to inform the design of a virtual reality exposure therapy: Results from Phase 1 of the  
635 AnxEpiVR clinical trial *Epilepsy Behav Rep.* 2023;21:100588.
- 636 71. Lennard S, Newman R, McLean B, Jory C, Cox D, Young C, et al. Improving nocturnal event  
637 monitoring in people with intellectual disability in community using an artificial intelligence camera  
638 *Epilepsy Behav Rep.* 2023;22:100603.
- 639 72. Hufford BJ, R.L. G, P.M. W. Home-based, interactive videoconferencing for adolescents with  
640 epilepsy and their families *Rehabilitation Psychology.* 1999:176-193.
- 641 73. Bruno E, Biondi A, Böttcher S, Vértes G, Dobson R, Folarin A, et al. Remote Assessment of  
642 Disease and Relapse in Epilepsy: Protocol for a Multicenter Prospective Cohort Study *JMIR Res*  
643 *Protoc.* 2020 Dec 16;9:e21840.
- 644 74. Saczynski JS, McManus DD, Goldberg RJ. Commonly used data-collection approaches in  
645 clinical research *Am J Med.* 2013 Nov;126:946-950.
- 646 75. Woudstra K, Tummers M, Rovers MM, Reuzel R. Innovators' views on involving users and  
647 patients in surgical device development: a qualitative interview study. 2021;11:e050801.
- 648 76. Vibhute SM, Engelmann J, Verbic T, Maier ME, Logothetis NK, Angelovski G. Synthesis  
649 and characterization of pH-sensitive, biotinylated MRI contrast agents and their conjugates with  
650 avidin *Organic & biomolecular chemistry.* 2012 Dec 6.
- 651 77. Dumanis SB, French JA, Bernard C, Worrell GA, Fureman BE. Seizure Forecasting from  
652 Idea to Reality. Outcomes of the My Seizure Gauge Epilepsy Innovation Institute Workshop *eNeuro.*  
653 2017 Nov-Dec;4.
- 654 78. Kuhlmann L, Lehnertz K, Richardson MP, Schelter B, Zaveri HP. Seizure prediction - ready  
655 for a new era *Nat Rev Neurol.* 2018 Oct;14:618-630.
- 656 79. Shum J, Friedman D. Commercially available seizure detection devices: A systematic review  
657 *J Neurol Sci.* 2021 Sep 15;428:117611.
- 658 80. Hagedorn TJ, Krishnamurty S, Grosse IR. An information model to support user-centered  
659 design of medical devices *J Biomed Inform.* 2016 Aug;62:181-194.

- 660 81. Staccini P, Joubert M, Quaranta JF, Fieschi D, Fieschi M. Modelling health care processes for  
661 eliciting user requirements: a way to link a quality paradigm and clinical information system design  
662 Int J Med Inform. 2001 Dec;64:129-142.
- 663 82. Smith V, Warty R, Nair A, Krishnan S, Sursas JA, da Silva Costa F, et al. Defining the  
664 clinician's role in early health technology assessment during medical device innovation – a systematic  
665 review BMC Health Services Research. 2019 2019/07/23;19:514.
- 666 83. Ly S, Runacres F, Poon P. Journey mapping as a novel approach to healthcare: a qualitative  
667 mixed methods study in palliative care BMC Health Services Research. 2021 2021/09/04;21:915.
- 668 84. Farzandipour M, Nabovati E, Sadeqi Jabali M. Comparison of usability evaluation methods  
669 for a health information system: heuristic evaluation versus cognitive walkthrough method BMC  
670 Medical Informatics and Decision Making. 2022 2022/06/18;22:157.
- 671 85. Dillman DA, Smyth JD, Christian LM. Internet, phone, mail, and mixed mode surveys: The  
672 tailored design method, 4th ed. Hoboken, NJ, US: John Wiley & Sons Inc; 2014.
- 673 86. Bitkina OV, Kim HK, Park J. Usability and user experience of medical devices: An overview  
674 of the current state, analysis methodologies, and future challenges International Journal of Industrial  
675 Ergonomics. 2020 2020/03/01;76:102932.
- 676 87. Gottgens I, Oertelt-Prigione S. The Application of Human-Centered Design Approaches in  
677 Health Research and Innovation: A Narrative Review of Current Practices JMIR Mhealth Uhealth.  
678 2021 Dec 6;9:e28102.
- 679 88. Martin JL, Clark DJ, Morgan SP, Crowe JA, Murphy E. A user-centred approach to  
680 requirements elicitation in medical device development: a case study from an industry perspective  
681 Appl Ergon. 2012 Jan;43:184-190.
- 682 89. U.S. Department of Health and Human Services FaDA, Center for Devices and Radiological  
683 Health, Office of Device Evaluation. Applying human factors and usability engineering to medical  
684 devices. Guidance for industry and Food and Drug Administration staff. FDA-2011-D-0469 2016.
- 685 90. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on  
686 medical devices aDE, Regulation (EC) No 178/2002 and Regulation (EC) No1223/2009 and repealing  
687 Council Directives 90/385/EEC and 93/42/EEC. 2017 O.J. (L 117) 1.
- 688
- 689

690

691 **Appendix 1 – Data Extraction Form**

Author details	Study Design	Country of the study	Year of publication	Objectives	Stages/phases of the development of medical device	Medical Device

692

693 **Figure legends**

694 Figure 1 – PRISMA Flowchart adopted for the present systematic review

695 Figure 2 – Number of publications per year (blue bars) and cumulative number (orange line)  
696 of publications from 1999 to 2023, as of \*November 30, 2023. (N=55)

697 Figure 3 – Types of medical devices developed and assessed by user involvement (N=55)

698 Figure 4 – Included publications by types of users (N=55), CG – caregivers; HP – Health  
699 Professionals; PWE – Patients with Epilepsy.

700 Figure 5 – Included publications by products lifecycle stages (N=55)

701 Figure 6 – Methods used for capturing user perspectives (N=55).

702

703 **Tables**

704 Table 1 – Product Lifecycle Stages (Adapted from Shah, Robinson <sup>16</sup>)

Medical Device Lifecycle Stage	Details
Concept	Starts with idea generation and includes technical, financial, and commercial assessment

Design	Involves product development process from (re)design to prototype development
Testing and trials	Starts with prototype testing in-house and includes trials in the real field
Production	Includes production on large scale supported by business and commercial rationale
Deployment	Includes product marketing, launch, and use in the real field

705


706 Table 2 – Methods used for capturing user perspectives by stages of the medical device  
707 lifecycle (N=55)


Concept Stage	Design Stage	Test and trials stages	Deployment stage
Survey (11)	Focus Groups (4)	Usability Testing (6)	Interviews (10)
Focus Groups (2)	Interviews (3)	Survey (8)	Survey (16)
Interview (3)	Survey (4)	Focus Groups (3)	Usability Testing (6)
Usability Testing (1)	Usability Testing (4)		Focus Groups (3)


708 *N – total publications included*

709


## Identification of studies via databases











Percentage of Studies (Total = 55)

